ClinicalTrials.gg
RecruitingNCT06258122TEMPO2Updated Jan 10, 2025

Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV

An observational study in HIV Infections, sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.

Planned enrollment
38th of 59
120 · median 200
Started
2024
with 8 others
Observational
59 of 278
13 open now
Primary completion
2024-12
later than 5 of 26 live
Registered
262nd of 278
by date
Lead sponsor
8 of 278
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

Among the 278 studies in HIV Infections with a site in France, this one is the 38th largest by planned enrollment of the 59 observational ones that give a count, is one of 9 that started in 2024, is one of 59 observational ones, reaches primary completion later than 5 of the 26 other live ones, and was the 262nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 278 studies in HIV Infections with a site in France, or all of them as a file.
02

Study summary

Main objective is:

  • To characterize the evolution of the immuno-virological profile of circulating blood cells and immune aging in patients who had participated to TEMPO-1 in 2007-2008
  • To evaluate the role of immune aging and inflammatory profile in the occurrence of comorbidities in HIV-infected individuals over a 15-year period

The alterations that affect the innate and adaptive immune cell compartments in HIV-infected patients are reminiscent of the process of immune aging, characteristic of old age. These alterations, the presumed cause of which is the chronic systemic immune activation established in patients, contribute to the depletion of lymphoid resources which probably leads to the decline of immune competence with the progression of HIV disease.

The comparison between HIV-1-infected patients and uninfected older adults goes beyond the mere appearance of immunosenescence and extends to the deterioration of a number of physiological functions linked to inflammation and to systemic aging.

By inducing persistent and lasting immune activation, HIV-1 infection is now considered a model of accelerated immunosenescence and systemic aging. During this process, the immune system quickly becomes exhausted, because the source of its exhaustion (i.e. HIV) cannot be eliminated.

To determine which factors may contribute to immunosenescence in HIV-1 infection, we propose an extensive immune and virological evaluation in patients who participated in a cross-sectional assessment of immune functions and TEMPO-1 viral reservoirs after 15 years of evolution in order to determine their immune and viral trajectories, to compare these trajectories with the major clinical events and the comorbidities occurring in them.

Read the detailed description

Growing old with HIV has become a reality thanks to major advances in antiretroviral therapy. Nearly 40 years after the discovery of the AIDS virus, there are more and more seniors living with HIV. Currently, the median age of HIV-positive people in France is 49 years old. 50% of HIV-positive people are over 50 years old (compared to 8.5% in 1993, 28% in 2010) and 16% over 60 years old. As for discoveries of seropositivity, 20% are in people over 50 years old. According to data from the Dutch ATHENA cohort, the proportion of HIV-infected people aged 50 and over is expected to increase to 73% in 2030.

Thus, if HIV infection has become a chronic disease, with lower mortality Investigator observe a consequent increase in age-related non-infectious comorbidities. Total healthy life expectancy remains reduced among PLHIV compared to uninfected people of the same age, and more than 50% of deaths are due to non-AIDS comorbidities. This polypathology occurs more frequently and at a younger age than in the general population, and notably combines cancers, risk factors and cardiovascular diseases, neurocognitive, bone diseases and chronic renal insufficiency. In 2030, it is estimated that 84% of PLHIV will have at least one of these comorbidities (vs. 29% in 2010), and that 28% will have at least 3, mainly cardiovascular. Some of these comorbidities are linked to the long-term use of ARVs (reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors) leading in particular to metabolic toxicities (dyslipidemia, insulin resistance), renal, bone, endothelial and mitochondrial. However, these toxicities have decreased over time and with pharmacological progress.

n addition to individual or environmental factors such as smoking, a sedentary lifestyle, and classic cardiovascular risk factors, HIV seems to contribute to an acceleration of aging.

The finding of an increased prevalence of non-HIV-related comorbidities such as cardiovascular disease, cancer, renal failure, liver disease, osteopenia and osteoporosis, as well as neurocognitive impairments is reminiscent of classic complications among elderly people with a biological profile marked by inflammation.

Another point in common between PLHIV and the elderly is their prolonged exposure to medications, often constituting polypharmacy.

Thus, antiretroviral molecules, taken by patients for decades for the majority of them, have unfortunately been responsible for various toxicities. First generation ARVs caused cellular disorders with mitochondrial damage for NRTIs such as zidovudine, didanosine or stavudine, metabolic disorders with protease inhibitors. However, the most recent class of molecules, INIs, is not free from toxicities. Indeed, several studies have shown abnormal weight gain with a risk of diabetes and more recently hypertension.

The biological hallmarks of aging are now better understood and include stem cell exhaustion, genomic instability, telomere attrition, impaired intercellular communication, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction and cellular senescence.

Immunologically, aging is associated with a decline in the competence of the immune system called immunosenescence. It is characterized by several features that affect the adaptive and innate immune compartment, as well as the hematopoietic compartment. It is also associated with a high level of secretion of pro-inflammatory cytokines at baseline, called "inflammation", leading to a decreased ability to mount an effective immune response to antigens. Investigators classically describe:

  • A decrease in the number of naive T lymphocytes (LT), secondary to thymic involution
  • An accumulation of memory cells and a restriction of the antigen receptor repertoire. This is notably determined by the involution of the thymus and the persistence of infectious agents such as cytomegalovirus,
  • Shortening of telomeres
  • Changes in the gene expression profile within T lymphocyte subpopulations affecting both surface markers and chemokine/cytokine receptors, effector molecules or transcription players.
  • A low-grade chronic systemic inflammatory condition called "inflamm-aging". It is characterized by the increased production of proinflammatory cytokines such as IL-1, IL-6, "tumor necrosis factor alpha" (TNF-α) as well as the production of C-reactive protein (CRP). The level of this proinflammatory state is associated with a worse prognosis in elderly patients: increased morbidity and mortality, sarcopenia and frailty.

These global immune changes observed with age contribute in particular to morbidity and mortality linked to infections (in particular via a reduction in the vaccine response) and cancers.

In 2007/2008, with the aim of describing and understanding the different viral and immune phenomena in treated or untreated PLHIV, we carried out a cross-sectional observational study on 240 patients carrying HIV-1.

The TEMPO study included a similar assessment of immune performance in an age- and sex-matched control population. This TEMPO study allowed us to establish the following conclusions:

  • massive depletion of CD4+ T cells occurs during HIV-1 infection, such that maintenance of adequate levels of CD4+ T cells depends primarily on the ability to replenish depleted lymphocytes, i.e. - say lymphopoiesis.
  • Marked deficiency of primary lymphoid immune resources is seen with failure to maintain adequate lymphocyte numbers.
  • Systemic immune activation has emerged as a major correlate of impaired lymphopoiesis, which can be partially reversed by prolonged antiretroviral therapy.

Importantly, disease progression despite elite control of HIV replication or virologic success on antiretroviral therapy has been associated with persistent damage to the lymphopoietic system or exhaustion of lymphopoiesis.

These results highlight the importance of primary hematopoietic resources in HIV pathogenesis and response to antiretroviral therapy.

TEMPO-2 is a cross-sectional study of PLHIV which will evaluate in depth the immuno-virological status of 100 patients studied in the same way 15 years ago (TEMPO-1). The complete history of clinical and biological events will be analyzed over their 15 years of follow-up in the same hospital.

The study includes two groups: one comprising HIV-infected patients (100 PLHIV) and the second comprising subjects not infected with HIV. Both groups participated in the initial study (TEMPO-1) conducted 15 years ago, with an in-depth assessment of immune and virological status.

The immune aging index of this HIV population will be compared to that of a control population of non-HIV subjects who both participated in TEMPO-1 in 2007/2008.

Investigator will focus on the dynamics of immune resources, particularly on hematopoietic progenitors. This approach will allow us to follow the biological trajectory of relevant immune factors and assess how these variables evolve over time between the two time points.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

HIV-infected individuals and non-HIV infected control group

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous participation to the TEMPO-1 study
  • 18 years of age or older
  • -infected individuals and non-HIV infected control group
  • Be affiliated or beneficiary of a social security scheme
  • Have signed the consent form.

Exclusion criteria

Exclusion Criteria:

  • Subject under " sauvegarde de justice " (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
120 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. measure of number of participants with the frequency of circulating leukocyte cells

    Assessment of 32 biomarkers by Cytek Aurora cytometry to identify more than 15 populations of immune cells

    Time frame: one year

  2. measureof number of participants with the number of hematopoietic stem cells in peripheral blood and their ability to develop a myeloid or lymphoid lineage in culture

    Assessment by culture

    Time frame: one year

Secondary outcomes

  1. measure of number of participants with cytokines and chemokines, being associated with the appearance of comorbidities

    Assessment by ultra-sensitive manner (Luminex and Quantérix technique)

    Time frame: one year

  2. Measure of number of participants with Microbial translocation markers

    Assessment by Elisa technique

    Time frame: one year

  3. Measure of number of participants with the HIV viral reservoir (DNA)

    Assessment by HIV DNA viral load (quantitative analysis) and by Sequencing of HIV in its DNA form (qualitative analysis: presence of resistance mutations, stop codons, insertions/deletions)

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Dec 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartActual
Apr 23, 2024
Primary completionActual
Dec 15, 2024
CompletionEst.
Dec 15, 2025
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06258122
Lead sponsor
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Apr 23, 2024
Primary completion
Dec 15, 2024
Completion
Dec 15, 2025 (estimated)
Last update
Jan 10, 2025

Study contacts

Yasmine DUDOIT
Contact
yasmine.dudoit@aphp.fr
+33142164181
Delphine SAUCE
Contact
delphine.sauce@sorbonne-universitec.fr
+33140779889

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion